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Context: Even though the majority of well-differentiated thyroid carcinoma (WDTC) is indolent,
a number of cases display an aggressive behavior. Cumulative evidence suggests that the
deregulation of DNA methylation has the potential to point out molecular markers associated
with worse prognosis.
Objective: To identify a prognostic epigenetic signature in thyroid cancer.
Design: Genome-wide DNA methylation assays (450k platform, Illumina) were performed in a
cohort of 50 nonneoplastic thyroid tissues (NTs), 17 benign thyroid lesions (BTLs), and 74 thyroid
carcinomas (60 papillary, 8 follicular, 2 Hu¨rthle cell, 1 poorly differentiated, and 3 anaplastic). A
prognostic classifier for WDTC was developed via diagonal linear discriminant analysis. The results
were compared with The Cancer Genome Atlas (TCGA) database.
Results: A specific epigenetic profile was detected according to each histological subtype. BTLs and
follicular carcinomas showed a greater number ofmethylated CpG in comparisonwith NTs, whereas
hypomethylation was predominant in papillary and undifferentiated carcinomas. A prognostic
classifier based on 21 DNA methylation probes was able to predict poor outcome in patients with
WDTC (sensitivity 63%, specificity 92% for internal data; sensitivity 64%, specificity 88% for TCGA
data). High-risk score based on the classifier was considered an independent factor of poor outcome
(Cox regression, P , 0.001).
Conclusions: The methylation profile of thyroid lesions exhibited a specific signature according to
the histological subtype. Ameaningful algorithm composed of 21 probes was capable of predicting
the recurrence in WDTC. (J Clin Endocrinol Metab 102: 4089–4099, 2017)
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Abbreviations: ATC, anaplastic thyroid carcinoma; BTL, benign thyroid lesion; DLDA,
diagonal linear discriminant analysis; FA, follicular adenoma; FTC, follicular thyroid carcinoma;
GP, good prognosis; Gai, G-protein a-i; HCC, Hu¨rthle cell carcinoma; LT, lymphocytic thy-
roiditis; NT, nonneoplastic thyroid tissue; PDTC, poorly differentiated thyroid carcinoma; PP,
poor prognosis; PTC, papillary thyroid carcinoma; TC, thyroid cancer; TCGA, The Cancer
Genome Atlas; WDTC, well-differentiated thyroid carcinoma.
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Thyroid cancer (TC) is the most common endocrinecancer (1) and comprises a group of tumors with
remarkably different features. Papillary thyroid carci-
noma (PTC) and follicular thyroid carcinoma (FTC) are
well-differentiated thyroid carcinomas (WDTCs) com-
prising 90% of all TC cases, whereas poorly differentiated
thyroid carcinoma (PDTC) and anaplastic thyroid carci-
noma (ATC) subtypes are extremely aggressive and less
frequently diagnosed (2). Despite the indolent biological
behavior of the well-differentiated carcinomas, these tu-
mors occasionally give rise to less differentiated and more
aggressive TCs (3). Moreover, a significant number of
patients with WDTC develop locoregional recurrences or
even radioiodine-resistant distant metastases (3).
DNA methylation in TC has been intensively studied,
and several markers have been described. To date, the
majority of these reports are based on the analysis of
candidate genes, focusing mainly in altered methylation
in CpG islands and their association with gene expres-
sion (4, 5).
Currently, a limited number of genome-wide meth-
ylation studies have been reported in TC, and most of
them are focused on PTC. Rodrı´guez-Rodero et al. (6),
using a low-density platform (Illumina Infinium HM
27K microarray) in eight samples (two PTC, two FTC,
two medullary, and two ATC), reported that different
methylation profiles were associated with distinct TC
subtypes. In 2014, The Cancer Genome Atlas (TCGA)
project reported the methylation profiles in a large cohort
of PTC cases (n = 496) performed in a high-density
platform (Illumina Infinium HM 450 array) (7). Blend-
ing different genomic approaches, the authors proposed a
PTC classification based on the molecular subtypes and
recognized potentially useful candidates to contribute to
management of the disease.
Aberrant DNA methylation has emerged as an impor-
tant mechanism involved in cancer progression. In PTC
samples, the methylation pattern of TIMP3, SLC5A8, and
DAPK was significantly associated with extrathyroidal
invasion, lymph node metastasis, multifocality, advanced
tumor stages, andBRAFmutation (8). In 2014,Wang et al.
(9) showed that RUNX3 site-specific hypermethylation
significantly increased the risk of PTC recurrence. Using
genome-widemethylation profiling (Illumina InfiniumHM
27K platform) in well-differentiated thyroid tumors and
validating the data in an independent series of cases,
Mancikova et al. (10) identifiedWT1 andEI24 as markers
for the risk of developing tumor recurrence. Overall, these
findings indicate that methylation and prognosis have been
poorly explored in TCs.
In this study, a comprehensive global methylation
(Illumina Infinium HM 450K microarray) analysis was
performed in a large cohort of cases including nonneo-
plastic thyroid tissues (NTs), benign thyroid lesions
(BTLs), and malignant thyroid lesions. Biomarkers and
biological pathways epigenetically regulated involved in
thyroid carcinogenesis were described. Subsequently, we
developed a prognostic classifier capable of predicting
the recurrence in patients with WDTC. Performance
of the DNA methylation-based algorithm was tested
against the TCGA database.
Materials and Methods
Patients
The samples were retrospectively obtained from patients
who underwent surgery at A.C. Camargo Cancer Center, S~ao
Paulo, Brazil. The study was approved by the Institutional
Ethics Committee (protocol no. 475.385). The patients were
advised of the procedures and provided written informed
consent. All FTC/Hu¨rthle cell carcinoma (HCC) and PDTC/
ATC samples available in the institutional tumor biobankwere
included, whereas the 60 PTC samples were selected from
patients treated with total thyroidectomy followed by radio-
iodine therapy (to standardize the treatment) and with $5
years of follow-up. Ten FTC/HCC, four PDTC/ATC, eight
follicular adenoma (FA), six nodular goiter, three lymphocytic
thyroiditis (LT), and 50 surrounding normal tissue samples
from patients with PTC were also included in this study. A
subset of samples (41 PTCs matched with adjacent NTs) used
in this analysis was previously reported (11). Clinical and
histopathological data for the malignant lesions are summa-
rized in the Table 1.
DNA extraction, bisulfite conversion, and DNA
methylation analysis
Genomic DNA from fresh frozen thyroid tissues was
extracted via the phenol-chloroform method and quantified by
Qubit® dsDNA BR Assay (Qubit® 2.0 Fluorometer, Life
Technologies, Carlsbad, CA). The DNA (500 ng) was bi-
sulfite converted with an EZ DNA Methylation-Gold™ Kit
(ZymoResearch, Irvine, CA) according to the manufacturer’s
recommendations.
Genome-wide methylation assays were performed with
the Human Methylation 450 BeadChip (Illumina, San
Diego, CA). The data were captured in Illumina HiScan
system, and the b values ranged from 0 (unmethylated) to 1
(methylated). R language was used for the methylation
analysis, as previously described (12). The quality control
parameters were followed, probes were filtered and normal-
ized, and the batch effects were assessed. Briefly, cross-reactive
probes ($49 bases), single nucleotide polymorphisms (mi-
nor allele frequency .5%), sex-associated probes (13), low-
quality probes (P . 0.05), and low bead count (,3) in $5%
of samples were excluded with the WaterRmelon package.
Data were normalized via the beta-mixture quantile normal-
ization method (14). The sva package was used to correct
the batch effects (15). The annotation was performed according
to the Illumina (hg19) and HUGO Gene Nomenclature
Committee.
Unsupervised hierarchical clustering analysis was performed
as described in Supplemental Material with BRB Array Tools
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version 4.4.0 software (Biometric Research Branch, National
Cancer Institute). Differentiallymethylated lociwere identified by
comparing BTL, PTC, FTC/HTC, and PDTC/ATC samples with
NT by using the limma package, adopting an adjusted P, 0.05
andmean delta beta (Db),20.2 or.+0.2. Rawmicroarray and
normalized data are available in Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/geo/) under specific accession
number (GSE97466).
Table 1. Clinicopathologic Characteristics of the Patients Enrolled in the Study
Characteristics
PTCa Other Subtypes
n % n %
Age
,55 y 51 85 4 28.6
$55 y 9 15 10 71.4
Sex
Female 44 73.3 10 71.4
Male 16 26.7 4 28.6
Histology (excluded PTC)
FTC — — 8 57.1
HCC — — 2 14.3
PDTC — — 1 7.1
ATC — — 3 21.4
Predominant variant (PTC only)
Classic 47 78.3 — —
Follicular 10 16.7 — —
Other 3 5.0 — —
Tumor dimension, cm
Median (interval) 1.3 — 2.3 —
(0.5–5.5) (0.9–13)
Micro-PTC (#1 cm) 25 41.7 — —
PTC (.1 cm) 35 58.3 — —
Extrathyroidal extension
No 30 52.6 7 53.8
Yes 27 47.4 6 46.2
Ni 3 — 1 —
Invasion
Vascular 2 3.4 5 38.5
Lymphatic 3 5.1 1 7.7
Both 1 1.7 2 15.4
No 53 89.8 5 38.5
Ni 1 — 1 —
Perineural invasion
No 42 93.3 10 23.1
Yes 3 6.7 3 76.9
Ni 15 1 —
Lymph node metastasis
No (cN0, pN0) 32 53.3 9 69.2
Yes (pN1) 28 46.7 4 30.8
Ni — — 1 —
Clinical evolution
Free of disease 44 73.3 5 71.4
Confirmed recurrence 16 26.7 2 28.6
Nib — — 7 —
Death
No 59 98.3 10 71.4
Yes 1 1.7 4 28.6
Follow-up (mo)c 83.8 — 63.3d —
(1.1–142.9) (4.0–139.4)
cN0, no clinical evidence of cancer in the regional lymph nodes; Ni, not informed; pN0, no pathological evidence of cancer in regional lymph nodes; pN1,
pathological confirmation of cancer in regional lymph nodes.
aPTC sampleswere enriched bymore aggressive features and recurrence in follow-up as a consequence of the inclusion criteria (only patients submitted to
total thyroidectomy followed by radioiodine therapy and patients without recurrence with $5 years of follow-up; all relapsed patients were enrolled).
bThree FTCs had ,5 years of follow-up with no recurrence, and 4 undifferentiated carcinomas showed ,6 months of follow-up after the diagnosis.
cData up to August 2014.
dOnly for FTC samples.
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Pathway enrichment analysis
In silico pathway analysis was conducted with Ingenuity
Pathway Analysis (IPA®, QIAGEN, Redwood City, CA, www.
qiagen.com/ingenuity) and KOBAS (version 2.0; http://kobas.
cbi.pku.edu.cn/home.do) software, comprising the list of dif-
ferentially methylated probes obtained in all comparisons (BTL
vs NT, PTC vs NT, FTC/HCC vs NT, and PDTC/ATC vs NT).
Only probes mapped within the interval until 200 bp and 200
to 1500 bp upstream of the transcription start site and those
in CpGs located within the 50UTR and in the first exon
were included.
DNA methylation-based algorithm to predict
well-differentiated (PTC and FTC/HCC) TC outcomes
Differentially methylated probes with potential biological
significance inmore aggressive subtypes of thyroidmalignancies
were initially selected to design a prognostic classifier. This first
step consisted in obtaining probes located in the promoter re-
gions by comparing between PDTC/ATC andNT.WDTC (PTC
and FTC/HCC) was grouped in poor prognosis (PP) and good
prognosis (GP) cases. Patients with confirmed recurrent loco-
regional disease (histological analysis) or distant metastasis
(conclusive imaging test) in the follow-up were categorized as
having WDTC-PP. The WDTC-GP group included only pa-
tients without any suspicion of active disease on clinical follow-
up (normal serum thyroglobulin levels and no evidence of
disease in the imaging screening) for $5 years (WDTC-GP: 43
PTC and 5 FTC). Because multifocal thyroid tumors are
probably related to an independent clonal origin (16) and to
obtain a more robust analysis, WDTC-PP exhibiting multifocal
primary tumors was excluded (WDTC-PP: 6 PTC and 2 FTC).
The Db .|0.1| was used as a criterion for the comparison
between WDTC-PP, NT, and BTL, which allowed the filtering
of probes exclusively altered inWDTC-PP andATC/PDTC. The
remaining probes were submitted to a diagonal linear dis-
criminant analysis (DLDA) method. The classification perfor-
mance was calculated with a leave-one-out cross-validation test
(BRBArray Tools version 4.4.0). The predictivemodel usedwas
based on scores stratified as low (NT range), intermediate
(below DLDA threshold), and high (above DLDA threshold).
Application of the prognostic classifier in PTC
samples from the TCGA database
TCGA database (http://tcga-data.nci.nih.gov/tcga/) was
used to test the performance of the DNA methylation-based
algorithm. Methylation (level 3, 450k Illumina platform; No-
vember 2015) and clinical datawere obtained fromTC samples,
which comprised only patients with PTC. Clinical data were
thoroughly evaluated under the same inclusion criteria pre-
viously defined in our study, resulting in 48 WDTC-GP and 14
WDTC-PP. The in silico data were used to test performance of
the mathematical model previously established without any
further adjustment.
Data processing and statistical analysis
Methylation quality control data and differential analysis were
performed in R and Bioconductor packages (methylumi, sva,
limma). The Bonferroni method was used to adjust P values for
multiple comparisons. DNA methylation b-values were graphi-
cally represented in a heatmap generated by BRB ArrayTools.
Disease-free survival analysis (SPSS version 21.0; Chicago, IL) was
performed via Kaplan–Meier estimator with log-rank test and
multivariable analysis with Cox (proportional hazards) regression,
adopting a two-tailed P , 0.05 value as significant.
Results
Global DNA methylation patterns unveils
TC subtypes
DNA methylation profiles of 74 tumor samples, 50
surrounding NTs, and 17 BTLs were investigated. Un-
supervised hierarchical clustering analysis revealed four
clusters with pathological and molecular differences
(Fig. 1A): cluster 1 was enriched with FAs, nodular
goiters, and minimally invasive FTCs, showing more
frequent hypermethylation events; cluster 2 displayed all
NT samples; cluster 3 comprised exclusively PTC sam-
ples, characterized by an evident methylation loss; and
cluster 4 exhibited all ATC/PDTC, lymphocytic chronic
thyroiditis, and the remaining FTC/HCC (most exten-
sively invasive). In contrast with the normal-like cluster
(cluster 2), cluster 4 was enriched by alterations involved
in immune response genes and clusters 1 and 3 by signal
transduction–related genes (Supplemental Table 1).
The comparison of BLT, PTC, FTC/HCC, and PDTC/
ATC vs NT (|Db| . 0.2 and adjusted P , 0.05) revealed
1753 differentially methylated probes in BTL (222
hypomethylated and 1531 hypermethylated), 3015 in
PTC (2773 hypomethylated and 242 hypermethylated),
5575 in FTC/HCC (1475 hypomethylated and 4100
hypermethylated), and 35,167 in PDTC/ATC (28,252
hypomethylated and 6195 hypermethylated) (Fig. 1B;
Supplemental Table 2).
DNA methylation changes were found in all genomic
regions. The follicular lesions presented hypomethylated
and hypermethylatedCpG sites closer to the transcription
start sites in gene body and intergenic regions (Fig. 1C).
Hypermethylation of CpG island regions was identified
in all comparisons, whereas hypomethylation was more
frequently observed outside the CpG islands (Fig. 1D). A
total of 620 hypermethylated probes was exclusively
found in BTL, 113 in PTC, 2244 in FTC/HCC, and 5411
in PDTC/ATC. Similarly, 95 hypomethylated probes
were found in BTL, 1,996 in PTC, 465 in FTC/HCC, and
26,734 in PDTC/ATC (Supplemental Fig. 1).
Molecular pathways associated with differentially
methylated promoter regions
In silico analysis using the list of promoter regions
hypomethylated and hypermethylated obtained in the
comparison between thyroid lesions and NTs revealed
the involvement of different pathways according to the
tumor subtype (Table 2; Supplemental Table 3). Acti-
vation of vitamin D receptors (VDRs) and retinoid X
receptors (RXRs) was associated with FTC and PTC (IPA
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Figure 1. Comparison of CpG site methylation regions between benign lesions, TCs, and surrounding NTs. (A) Unsupervised hierarchical
clustering analysis of the methylation profiles of thyroid tissues using the most variable probes within the platform (8016 probes). Four major
groups were detected and defined by the most variable probes. The rows indicate the CpG sites, and the columns indicate the samples. (B)
Percentage of hypermethylated (red) and hypomethylated (green) probes in BTL, PTC, FTC/HCC, and PDTC/ATC. (C) CpG site proportions by
location relative to promoter, gene body, and intergenic region, according to Illumina 450 K annotation. (D) CpG site proportions by location
relative to CpG island regions, according to Illumina 450 K annotation.
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P, 0.05), whereas the G-protein alpha-i (Gai) signaling
pathway was identified as deregulated in ATC/PDTC
(Supplemental Fig. 2, Supplemental Table 3) (adjusted
P , 0.05).
Prognostic classifier performance in
well-differentiated TC
An altered DNA methylation pattern in a specific
locus has the potential to be a useful biomarker for the
identification of aggressive TC subtypes. Based on this
premise, a prognostic classifier was designed with 7700
probes mapped in the promoter regions obtained from
the comparison between PDTC/ATC and NT. A total of
21 probes showed Db ,20.1 or .+0.1 comparing
WDTC-PP with WDTC-GP cases, with 17 hypomethy-
lated (OR6K2, LAIR2, PFKFB2, OR4K15, NLRP11,
OR9G4, THSD7B, OR2M3, OR52B2, OR2T6,
FFAR2, TN3, OR52M1, DCD, ADGRE2, HRH1, and
CXXC5) and four hypermethylated (GPR21, MBP,
YPEL4, and ATP6V0C) in the WDTC-PP group
Table 2. Top 10 Significant Canonical Pathways Identified in the Comparisons by Ingenuity Pathway Analysis
Software
Analysis
Pathway (Ingenuity Pathway
Analysis)
Prediction State
(z Score)
Genes Found/
Database
P (Fisher
Exact Test)
P (Benjamini–Hochberg
Correction)
BTL vs NT Reelin signaling in neurons — 6/79 0.002 0.438
eNOS signaling Inhibited (21.9) 8/142 0.003 0.438
Leukocyte extravasation signaling Inhibited (20.7) 9/198 0.006 0.443
IL-4 signaling — 5/76 0.009 0.443
CCR3 signaling in eosinophils — 6/117 0.014 0.443
FAK signaling — 5/87 0.015 0.443
L-dopachrome biosynthesis — 1/1 0.017 0.443
RhoA signaling Inhibited (22.2) 6/122 0.017 0.443
Amyotrophic lateral sclerosis
signaling
— 5/98 0.025 0.443
IL-12 signaling and production in
macrophages
— 6/135 0.026 0.443
FTC/HCC
vs NT
Inhibition of matrix metalloproteases — 6/39 0.014 0.946
Leukocyte extravasation signaling Inhibited (21.4) 18/198 0.015 0.946
eNOS Signaling Inhibited (21.7) 14/142 0.016 0.946
Tec kinase signaling Inhibited (21.9) 15/158 0.017 0.946
HGF signaling Inhibited (22.1) 11/105 0.020 0.946
Reelin signaling in neurons — 9/79 0.021 0.946
FAK signaling — 9/87 0.036 0.946
Fatty acid a-oxidation — 3/16 0.047 0.946
VDR/RXR activation Activated (0.4) 8/78 0.049 0.946
Factors promoting cardiogenesis in
vertebrates
— 9/92 0.049 0.946
PTC vs NT TREM1 signaling Activated (2.8) 8/74 ,0.001 0.044
IL-10 signaling — 7/68 ,0.001 0.079
RhoGDI signaling Inhibited (22.3) 10/173 0.003 0.192
Signaling by Rho family GTPases Activated (2.1) 12/234 0.003 0.192
The visual cycle — 3/15 0.003 0.192
LXR/RXR activation Inhibited (22.1) 8/121 0.003 0.192
VDR/RXR activation Activated (2.2) 6/78 0.005 0.232
LPS/IL-1 mediated inhibition of RXR
function
Activated (1.0) 11/219 0.005 0.232
Integrin signaling Activated (3.0) 10/201 0.008 0.301
Role of JAK1 and JAK3 in gc
cytokine signaling
— 5/63 0.009 0.301
PDTC/ATC
vs NT
Agranulocyte adhesion and
diapedesis
— 58/189 ,0.001 0.001
Atherosclerosis signaling — 41/124 ,0.001 0.002
LXR/RXR activation Inhibited (21.0) 39/121 ,0.001 0.004
Transcriptional regulatory network
in embryonic stem cells
— 18/40 ,0.001 0.004
FXR/RXR activation — 39/127 ,0.001 0.009
Granulocyte adhesion and
diapedesis
— 50/177 ,0.001 0.009
GABA receptor signaling — 23/67 ,0.001 0.031
Estrogen biosynthesis — 15/37 ,0.001 0.033
Gai signaling Activated (2.8) 35/120 ,0.001 0.033
Gas signaling Activated (1.0) 32/109 ,0.001 0.045
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(Table 3). These 21 probes were submitted to a DLDA to
train a prognostic predictor classifier, which was able
to distinguish WDTC-PP from WDTC-GP with 63%
sensitivity and 92% specificity (63% sensitivity and
90% specificity in leave-one-out cross-validation). Perfor-
mance according to stratification of the predictive model in
low, intermediate, and high scores is shown in Fig. 2A.
Disease-free survival analysis revealed a higher risk of
recurrence according to the score categories (Fig. 2B).
Multivariable analysis showed that high score is an in-
dependent factor for lower disease-free survival (P ,
0.001; odds ratio 31.0; 95% CI, 4.9 to 195.6) (Supple-
mental Table 4). The prognostic classifier found in our
analysis was tested with the TCGA methylation data in
PTC samples, confirming a similar predictive accuracy
(64% sensitivity and 88% specificity) (Fig. 2C) and lower
disease-free survival in cases with high scores (Fig. 2D).
Contrasting the methylation definition of “high risk”
with the clinical–pathological “high risk” classification
(17), the latter presented lower sensitivity (21% to 38%)
and slightly higher specificity (96% to 98%) (Supple-
mental Fig. 3). The individual clinical pathological data
and algorithm scores of internal and external (TCGA)
data sets are described in Supplemental Table 5.
Discussion
The thyroid samples derived from follicular cells revealed
high methylation variability, as showed in the un-
supervised hierarchical clustering analysis. From the four
major groups exposed as results of this analysis, LT was
grouped with highly aggressive tumors including un-
differentiated or poorly differentiated tumors and exten-
sively invasive FTCs (cluster 4). Lymphocytic thyroiditis
is a chronic autoimmune thyroid disease enriched with
immune cell infiltration and inflammatory cytokines (18,
19), similar to highly proliferative and invasive thyroid
tumors (20). Interestingly, an enrichment of genes related
to immunological response was detected in cluster 4.
Therefore, an important source of the methylation het-
erogeneity may be the inflammation response, as pre-
viously described in molecular profiling studies of thyroid
tumor samples (21, 22).
The methylation profiles of the sample groups com-
pared with NTs revealed that CpG site hypermethylation
wasmore frequently observed in benign lesions and FTCs
and hypomethylation in papillary and poorly differen-
tiated or anaplastic carcinomas. These findings point out
distinct epigenetic mechanisms related to the develop-
ment or progression of thyroid lesions according to
histological subtype.
Changes in the methylation pattern of benign lesions
have also been reported (23), suggesting the relevance of
this process at early stages of tumorigenesis. CpGs with
methylation gains were more frequently observed in
FTCs (4100) than in BTLs (1531) compared with NTs.
Mancikova et al. (10) reported similar findings com-
paring gene promoter methylation profiles of FTCs and
FAs. We also found aberrant methylation in gene body in
both lesions, BTL and FTC. In addition to the mor-
phological and genetic similarities described in adenomas
(in our analysis, eight FAs were included in the BTL
Table 3. The Prognostic Classifier Comprising 21 Probes Included 4 Hypermethylated (DLDA Positive Values)
and 17 Hypomethylated (DLDA Negative Values) Probes
Probe ID Gene Symbol Promoter Region Db ATC/PDTC–NT Db WDTC-PP–WDTC–GP DLDA Score
cg00119186 OR6K2 1st exon 20.411 20.105 216.72
cg08905487 LAIR2 TSS200 20.406 20.134 212.14
cg02710090 PFKFB2 TSS1500 20.253 20.109 211.41
cg07531287 OR4K15 1st exon 20.280 20.112 210.68
cg25730098 NLRP11 50UTR 20.321 20.118 210.65
cg03178489 OR9G4 1st exon 20.307 20.104 29.33
cg08231096 THSD7B TSS200 20.352 20.101 29.23
cg07598464 OR2M3 1st exon 20.388 20.131 28.41
cg21966764 OR52B2 TSS1500 20.263 20.110 27.31
cg06846214 OR2T6 TSS1500 20.337 20.109 26.38
cg20199836 FFAR2 TSS200 20.369 20.102 26.06
cg17372806 RTN3 TSS1500 20.330 20.103 25.81
cg03316101 OR52M1 1st exon 20.309 20.123 25.03
cg01687040 DCD TSS1500 20.355 20.103 24.75
cg04103514 ADGRE2 TSS200 20.379 20.122 24.70
cg06457736 HRH1 TSS200 20.460 20.120 23.48
cg19628988 CXXC5 50UTR 20.362 20.104 23.28
cg14115756 GPR21 TSS1500 0.457 0.117 4.07
cg03560685 MBP TSS1500 0.513 0.109 4.98
cg22705929 YPEL4 TSS1500 0.324 0.122 5.66
cg05884711 ATP6V0C TSS1500 0.341 0.191 9.60
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group) and FTCs (24), these entities also shared an ele-
vated number of hypermethylated CpGs (479) (Supple-
mental Fig. 1).
PTCs displayed fewer aberrantly methylated genes
compared with other carcinoma subtypes. In accor-
dance with previous studies using methylation arrays in
PTC samples, loss of methylation in both promoter and
gene body regions was more frequently observed than
hypermethylation (10, 25). Moreover, a high degree of
loss of methylation was found in more aggressive
undifferentiated TCs, a similar finding previously de-
scribed in acute myeloid leukemia and in breast cancer
progression (26, 27). All histological subtypes of thyroid
lesions exhibited hypermethylation in CpG island pro-
moters as frequent event; hypomethylation in CpGs
outside the promoter regions was also detected. These
findings are in agreement with global methylation studies
performed in TC (6, 10).
In silico pathway analysis via probes mapped in the
promoter region revealed the activation of the Gai
Figure 2. Prognostic evaluation based on the methylation data. (A, C) Predictive model values based on the 21 probes used in the stratification of
the cases in three categories: low, intermediate, and high risk using both internal and external data (TCGA). (B, D) Disease-free survival curves in
well-differentiated carcinomas stratified into low, intermediate, and high risk according to the classifier in both internal and external data (TCGA).
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pathway in poorly differentiated and undifferentiated
carcinomas. These G proteins stimulate the kinase ac-
tivity of cSRC protein (28), which is involved in a variety
of cell functions, including survival, proliferation, and
cell migration. In our study, Gai, SHC, and RAS were
hypomethylated, and RAP1GAP (negative regulator of
Gai pathway) was hypermethylated. Using gene ex-
pression analysis, we previously reported RAP1GAP
down-expression in PTC samples (21). In thyroid cell
lines, RAP1GAP downregulation was associated with
migratory and invasive properties (29). Moreover,
RAP1GAP promoter hypermethylation and down-
regulation were reported in the most aggressive forms of
TC (30). Our data give additional support to the in-
volvement of the SRC upstream regulators in the prog-
nosis of poorly differentiated and undifferentiated TCs.
Previously, we detected the VDR and RXR activation
pathway as potentially deregulated in PTC samples (21),
which is probably related to DNA methylation changes.
In the current study, we demonstrated the predicted ac-
tivation of this pathway in FTC samples but not in PDTC
and ATC. These results are in agreement with high ex-
pression levels of VDR (31) and RXR (32) described in
differentiated TC compared with normal tissues. Fur-
thermore, high expression levels of VDR in patients with
ATC are considered rare (31). These results reinforce that
methylation is an importantmechanism of gene regulation
related to tumor progression, because of the importance of
VDRs and RXRs in growth and cell differentiation.
Studies aiming to identify reliable markers associated
with TC aggressiveness at the time of diagnosis can result
in individualized treatment. Tumors harboring BRAF
mutations have been associated with more aggressive
phenotypes (3). Recently, TERT promoter mutations
were associated with a worse prognosis, especially in BRAF
mutated cases. Approximately 9% of PTCs were positive
for TERT mutations (particularly C228T and C250T),
whereas PDTCs and ATCs showed a higher frequency of
mutations (40% and .70%, respectively) (33).
Methylation analysis has been described as a potent
strategy to predict outcomes in several cancer subtypes. In
PTCs, RUNX3 hypermethylation (9) and TSHR hypo-
methylation (34) were reported as related to tumor re-
currence. We found RUNX3 hypermethylated in the
promoter region (13 probes) in PDTC/ATC, but no as-
sociationwith recurrencewas observed.Nonetheless, one
probe (cg00117172) mapped in the nonpromoter region
of RUNX3 (body gene) was hypermethylated in both
comparisons, PDTC/ATC vs NT (Db = 0.313) and
WDTC-PP vsWDTC-GP (Db = 0.102), reinforcing their
potential as biomarkers of tumor aggressiveness.
In this study, using rigorous inclusion criteria aiming
to minimize confounding factors, we described a DNA
methylation model to predict WDTC outcome, in terms
of recurrence. The model initially was designed based
on the assumption that promoter regions differentially
methylated in anaplastic and poorly differentiated tu-
mors, which by definition present PP, could also be in-
volved in the more aggressive forms of well-differentiated
carcinomas. After filtering the initial list by comparing
WDTC-PPwithWDTC-GP, NT, and BTL, we designed a
mathematical model based on 21 probes. Considering
that LT and highly aggressive tumors presented similar
methylation profiling, which may be explained by the
strong influence of inflammation, the comparison of
WDTC-PP with BTL was an essential step to avoid the
prediction of inflammatory lesions as high-risk cases. In
our cases, no significant differences were found consid-
ering the LT in the groups predicted by the DNA
methylation prognostic model (low, 30%; intermediate,
19%; high, 33%; Fisher exact test P = 0.541).
From the probes included in the algorithm, 17 of 21
showed loss of methylation. Interestingly, 7 of 17 probes
are mapped in the promoter regions of olfactory receptor
genes. Olfactory receptors are G protein–coupled re-
ceptors, which have been reported as mediating tumor
proliferation, invasiveness, and metastasis (35, 36). Al-
though these genes are included among those described in
the algorithm, their role in TC prognosis remains to be
clarified.
Interestingly, high expression of PFKFB2, a hypo-
methylated gene found in the classifier, was reported as
being associated with advanced TNM stage and also was
implied in poor overall survival in hepatocellular carci-
noma (37). In TC, PFKFB2 overexpression was described
in older patients (.40 years old) and associated with
PP (38).
The methylation signature of 21 probes herein in-
troduced was capable of discriminating 86% of the
samples according to the outcome, demonstrating high
specificity (90%) but lower sensitivity (63%). Therefore,
more than half of WDTC-PP cases would be detected,
with no further implications for overtreatment, which is a
well-discussed issue in the management of patients with
WDTC (39). A similar predictive power was observed
when the algorithm was tested in an independent in silico
data set of PTC samples (TCGA), which correctly clas-
sified 82% of the samples (64% sensitivity and 88%
specificity).
Performance of the methylation algorithm was com-
pared with TERT promoter mutation (C228T and
C250T) with the TCGA data (data not shown). Fifty of
the 62 PTC samples included in the TCGA cohort pre-
sented TERT promoter sequences. Four of these 50 cases
were positive for the mutation: Twowere classified by the
methylation algorithm as intermediate (all disease-free)
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and two as high risk (one disease-free and one relapsed
case). In addition, the mutation assay was unable to
identify relapsed patients with TC (8 of 9). Therefore, the
methylation algorithm and TERT promoter mutation
analysis showed no overlapping. The performance of
our methylation algorithm was also compared with the
American Thyroid Association guidelines (17), revealing a
distinct set of high-risk cases. The high risk prediction
based on molecular or clinical–pathological methods in-
creased the sensitivity to 75%and specificity to 90% in the
internal data set and 71% sensitivity and 88% specificity
in the TCGA data set. These findings suggested that the
methylation test would be feasible in clinical routines in
combination with conventional stratification methods. A
multiplexedmethylation assay could be used to increase its
applicability, similar to other tools described in the liter-
ature (40).
Conclusions
Thyroid carcinoma subtypes, which present the same
cellular origin, showed different DNA methylation pro-
filing. A prognostic classifier based on the methylation
changes in a small number of loci was reported, which
could correctly classify a subset of patients with WDTC
with poor outcomes. Even though our study and the
TCGA data revealed a limited number of cases classified
as WDTC-PP, the rigorous criteria used to select the
patients and the power to predict recurrence in both
analyses reinforce that this classifier has the potential to
be applied as a prognostic tool useful for making ther-
apeutic decisions in TC.
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